Literature DB >> 3537734

MRC OX-45 antigen: a leucocyte/endothelium rat membrane glycoprotein of 45,000 molecular weight.

J Arvieux, A C Willis, A F Williams.   

Abstract

Monoclonal antibodies MRC OX-45 and OX-46 detect identical or juxtaposed antigenic determinants on a novel rat membrane molecule that plays a possible role in macrophage suppression of antigen-induced T-cell responses. These antibodies react with most mature hematopoietic cells and their bone-marrow precursors, vascular endothelium and some connective tissue. The OX-45 antigens were purified from brain (mainly endothelium) and spleen by immunoaffinity chromatography, and were found to be glycoproteins with apparent Mr 43,000 and 45,000, respectively, as determined by SDS-PAGE analysis. The amino acid compositions of the two preparations were very similar but with no distinguishing features. The broad pattern of distribution was not the result of fortuitous cross-reaction of the MAbs as a single N-terminal sequence was obtained from mixed spleen populations of cells. Carbohydrate compositions of the brain and spleen molecules differed both in absolute amount (22 and 41% by weight, respectively) and in the ratios of various saccharides reflecting overall differences in the patterns of glycosylation between the two tissues. MRC OX-45 IgG showed an heterogeneity in the Mr of its H chain due to the attachment, in some molecules, of carbohydrate structures to the Fd fragment.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3537734     DOI: 10.1016/0161-5890(86)90129-x

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  11 in total

Review 1.  Antibody variable region glycosylation: biochemical and clinical effects.

Authors:  A Wright; S L Morrison
Journal:  Springer Semin Immunopathol       Date:  1993

2.  Blood-brain barrier protein recognized by monoclonal antibody.

Authors:  N H Sternberger; L A Sternberger
Journal:  Proc Natl Acad Sci U S A       Date:  1987-11       Impact factor: 11.205

3.  A human cell-surface glycoprotein that carries Cromer-related blood group antigens on erythrocytes and is also expressed on leucocytes and platelets.

Authors:  F A Spring; P A Judson; G L Daniels; S F Parsons; G Mallinson; D J Anstee
Journal:  Immunology       Date:  1987-10       Impact factor: 7.397

4.  Endothelium-derived relaxing factor and the effects of acetylcholine and histamine on resistance blood vessels.

Authors:  R Bhardwaj; P K Moore
Journal:  Br J Pharmacol       Date:  1988-11       Impact factor: 8.739

5.  Identification, by protein sequencing and gene transfection, of sgp-60 as the murine homologue of CD48.

Authors:  J G Cabrero; G J Freeman; W S Lane; H Reiser
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-15       Impact factor: 11.205

6.  Different culture methods lead to differences in glycosylation of a murine IgG monoclonal antibody.

Authors:  T P Patel; R B Parekh; B J Moellering; C P Prior
Journal:  Biochem J       Date:  1992-08-01       Impact factor: 3.857

7.  Homotypic adhesion of rat B cells, but not T cells, in response to cross-linking of CD48.

Authors:  D Garnett; A F Williams
Journal:  Immunology       Date:  1994-01       Impact factor: 7.397

8.  The MRC OX-45 antigen of rat leukocytes and endothelium is in a subset of the immunoglobulin superfamily with CD2, LFA-3 and carcinoembryonic antigens.

Authors:  N Killeen; R Moessner; J Arvieux; A Willis; A F Williams
Journal:  EMBO J       Date:  1988-10       Impact factor: 11.598

9.  Blast-1 possesses a glycosyl-phosphatidylinositol (GPI) membrane anchor, is related to LFA-3 and OX-45, and maps to chromosome 1q21-23.

Authors:  D E Staunton; R C Fisher; M M LeBeau; J B Lawrence; D E Barton; U Francke; M Dustin; D A Thorley-Lawson
Journal:  J Exp Med       Date:  1989-03-01       Impact factor: 14.307

10.  CD48 is a counter-receptor for mouse CD2 and is involved in T cell activation.

Authors:  K Kato; M Koyanagi; H Okada; T Takanashi; Y W Wong; A F Williams; K Okumura; H Yagita
Journal:  J Exp Med       Date:  1992-11-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.